Lindsay Fischer | Authors

Articles

Trastuzumab Deruxtecan Preserves QOL in HER2-Low Breast Cancer

September 11, 2022

Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.